Other

The Brigham and Women's Hospital, Inc.

Velico Medical, Inc.

Health Research, Inc.

Sackstein, Robert

Robert Sackstein

Qiyong Peter Liu

Karin M Hoffmeister

Khushi L Matta

Ralph J Bernacki

Charles J Dimitroff

Moheswar Sharma

Brajeswar Paul

Methods of treatment are provided herein, including administration of a population cells modified to enforce expression of an E-selectin and/or an L-selectin ligand, the modified cell population having a cell viability of at least 70% after a treatment to enforce such expression.

Methods to improve cell therapy

The present disclosure provides, inter alia, compositions and methods for enforcing a pattern of cell surface fucosylated lactosaminyl glycans on a human cell. In certain embodiments, the compositions and/or methods utilize one or more members of the α(1,3)-fucosyltransferase family. In certain embodiments, a process for custom-modifying a fucosylated lactosaminyl glycan on a human cell is disclosed.

Compositions and methods for enforcing fucosylation of lactosaminyl glycans in human cells with alpha(1,3)-fucosyltransferases

Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.

Compositions and methods for modifying cell surface glycans

The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.

Hematopoietic progenitor cell populations having affinity for E-selectin / L-selectin

The present invention relates to a platelet additive solution (PAS) having an amount of one or more &#x3b2;-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof.

Platelet additive solution having a beta-galactosidase inhibitor

The present invention relates to a platelet protection solution (PPS) having an amount of one or more &#x3b2;-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PPS components that include a salt, a citrate source, a carbon source, or any combination thereof.

Platelet protection solution having beta-galactosidase and sialidase inhibitors

Platelet additive solution having a &#x3b2;-galactosidase inhibitor

The invention features methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.

Method for increasing the E-selectin binding affinity of a population of cells expressing a CD44 polypeptide

The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO activity. The inhibitors may be administered in conjunction with G-CSF therapy. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab')and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics (including aptamers) and organic compounds (e.g., glycomimetics).

Methods of treating complications and disorders associated with G-CSF administration

Methods for modifying cell surface glycans

Methods and compositions for treating cells with cytokines are provided herein.

Growing community of inventors

Sudbury, MA, United States of America

Robert Sackstein